Voyager Therapeutics has entered into a License and Collaboration Agreement with Novartis Pharma AG to provide rights to Novartis for certain proprietary adeno-associated virus (AAV) capsids for use in gene therapy products for spinal muscular atroph
AI Assistant
VOYAGER THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.